Protective effects of Bisoprolol against anthracycline-induced cardiomyopathy in breast cancer patient

Protective effects of Bisoprolol against anthracycline-induced cardiomyopathyin in breast cancer patient

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130701013828N8

Enrollment

Registered

2021-10-04

Start date

2021-10-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemotherapy induced cardiomyopathy in breast cancer patients.

Interventions

Intervention 1: Intervention group: 2.5 mg Bisoprolol tablets from Abidi company are taken daily from one week before the start of chemotherapy until the end of the chemotherapy course. Intervention 2

Eligibility

Sex/Gender

Female

Age

25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with breast cancer Patients with indication for AC (doxorubicin hydrochloride (Adriamycin) and cyclophosphamide) regimen for chemotherapy Patients agreement

Exclusion criteria

Exclusion criteria: Patients non compliance Patients who have cardiovascular problems Have previously undergone chest radiotherapy Patients who have allergy to Bisoprolol Patients currently taking beta-blockers Patients who have contraindicated for use beta blockers.

Design outcomes

Primary

Measure	Time frame
LVEDV(left ventricular end diastolic volume). Timepoint: The first measurement is before the start of chemotherapy and before the intervention, then three months and six months after chemotherapy and during the intervention. Method of measurement: Specialized echocardiography.;(GLS)global longitudinal strain. Timepoint: The first measurement is before the start of chemotherapy and before the intervention, then three months and six months after chemotherapy and during the intervention. Method of measurement: Specialized echocardiography.;LVESD(left ventricular end systolic diameter). Timepoint: The first measurement is before the start of chemotherapy and before the intervention, then three months and six months after chemotherapy and during the intervention. Method of measurement: Specialized echocardiography.;LVEDD(left ventricular end diastolic diameter). Timepoint: The first measurement is before the start of chemotherapy and before the intervention, then three months and six months after chemotherapy and during the intervention. Method of measurement: Specialized echocardiography.;LVESV(left ventricular end systolic volume). Timepoint: The first measurement is before the start of chemotherapy and before the intervention, then three months and six months after chemotherapy and during the intervention. Method of measurement: Specialized echocardiography.	—

Measure

Time frame

LVEDV(left ventricular end diastolic volume). Timepoint: The first measurement is before the start of chemotherapy and before the intervention, then three months and six months after chemotherapy and during the intervention. Method of measurement: Specialized echocardiography.;(GLS)global longitudinal strain. Timepoint: The first measurement is before the start of chemotherapy and before the intervention, then three months and six months after chemotherapy and during the intervention. Method of measurement: Specialized echocardiography.;LVESD(left ventricular end systolic diameter). Timepoint: The first measurement is before the start of chemotherapy and before the intervention, then three months and six months after chemotherapy and during the intervention. Method of measurement: Specialized echocardiography.;LVEDD(left ventricular end diastolic diameter). Timepoint: The first measurement is before the start of chemotherapy and before the intervention, then three months and six months after chemotherapy and during the intervention. Method of measurement: Specialized echocardiography.;LVESV(left ventricular end systolic volume). Timepoint: The first measurement is before the start of chemotherapy and before the intervention, then three months and six months after chemotherapy and during the intervention. Method of measurement: Specialized echocardiography.

—

Secondary

Measure	Time frame
Cardiotoxicity. Timepoint: before chemotherapy and end of chemotherapy. Method of measurement: Echocardiography.;Dizziness. Timepoint: after start of drug. Method of measurement: Ask patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ahmad Mirdamadi

Islamic Azad University

drsamirdamadi@yahoo.com+98 31 4229 1111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026